Forecast: Non-Small Cell Lung Cancer in China - New Market Research Report
Pharmaceutical companies have been attracted by the high incidence of NSCLC in China and the pipeline has grown substantially. The treatment of NSCLC will continue to evolve as key brands come off patent and new therapies are launched in the Chinese market.
View full press release